Nuwellis Increased CMS Reimbursement Rate for Aquadex SmartFlow

 Reimbursement rate to increase 397% per day effective January 1, 2025

New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting

Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) will reassign the Aquadex ultrafiltration code to the outpatient reimbursement level most consistent with administration of ultrafiltration therapy and cost of treatment. Effective January 1, 2025, the payment rate will increase 397% from $413 to $1,639 per day.

https://www.globenewswire.com/news-release/2024/11/04/2974081/26106/en/Nuwellis-Receives-Increased-Reimbursement-Rate-for-Aquadex-SmartFlow-Therapy-from-the-Centers-for-Medicare-and-Medicaid.html